Skip to main content
Clinical Trials/CTRI/2022/04/041912
CTRI/2022/04/041912Not yet recruitingNot Applicable

Development of scale for the assessment of strength of Satva and to evaluate its influence on RÄjayaká¹£mÄ with special reference to Pulmonary Tuberculosis

Institute of Medical Science Banaras Hindu University Varanasi Uttar Pradesh India1 site in 1 country75 target enrollmentStarted: April 25, 2022Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
75
Locations
1
Primary Endpoint
To evaluate the type of Satva and its role in response to the treatment of Pulmonary Tuberculosis.

Study Overview

Brief Summary

This study is a single group prospective observational study to evaluate the strength of satva and its role in Pulmonary Tuberculosis. The primary outcome will association of the type of Satva and its role in response to the treatment of Pulmonary Tuberculosis. The secondary outcome will be the association of types of Satva with adverse reactions and complications of Pulmonary Tuberculosis.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18.00 Year(s) to 70.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • •1.Confirmed pulmonary tuberculosis patients irrespective of gender 2.Patients with well controlled comorbid conditions 3.Age group between 18-70 years.

Exclusion Criteria

  • •1.Not willing to complete the consent process as describe in proforma.
  • •2.Inability to comply with study procedures and methods.
  • •3.HIV patients.

Outcomes

Primary Outcomes

To evaluate the type of Satva and its role in response to the treatment of Pulmonary Tuberculosis.

Time Frame: 1.5yr

Secondary Outcomes

  • To evaluate the association of types of Satva with adverse reactions and complications of Pulmonary Tuberculosis.(1.5 yr)

Investigators

Sponsor
Institute of Medical Science Banaras Hindu University Varanasi Uttar Pradesh India
Sponsor Class
Government medical college

Study Sites (1)

Loading locations...

Similar Trials